| David F Skanchy, | |
|
1000 Wall St, Ann Arbor, MI 48105-1912 | |
| (734) 764-4190 | |
| Not Available |
| Full Name | David F Skanchy |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Location | 1000 Wall St, Ann Arbor, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649831462 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 4301508741 (Michigan) | Primary |
| Entity Name | Regents Of The University Of Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568495299 PECOS PAC ID: 3779496856 Enrollment ID: O20031118000092 |
News Archive
AFFiRiS AG will explore ProBioGen's proprietary Human Artificial Lymph Node Technology (HuALN) as analytical tool for its AFFITOME®-based vaccination concept. Under the contract with ProBioGen, AFFiRiS will evaluate the HuALN technology as a human organoid model to investigate drug-related effects in the context of the human immune system in order to select vaccine candidates best suited to be applied in humans.
PDL BioPharma, Inc. today announced the settlement and final results of its offer to exchange up to $180,000,000 in aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015 (Old Notes), for a like principal amount of new 2.875% Series 2012 Convertible Senior Notes due 2015 (New Notes), and a cash payment.
Eli Lilly and Company and Boehringer Ingelheim today announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David F Skanchy, 3621 S State St, Ann Arbor, MI 48108-1633 Ph: (734) 647-5299 | David F Skanchy, 1000 Wall St, Ann Arbor, MI 48105-1912 Ph: (734) 764-4190 |
News Archive
AFFiRiS AG will explore ProBioGen's proprietary Human Artificial Lymph Node Technology (HuALN) as analytical tool for its AFFITOME®-based vaccination concept. Under the contract with ProBioGen, AFFiRiS will evaluate the HuALN technology as a human organoid model to investigate drug-related effects in the context of the human immune system in order to select vaccine candidates best suited to be applied in humans.
PDL BioPharma, Inc. today announced the settlement and final results of its offer to exchange up to $180,000,000 in aggregate principal amount of outstanding 2.875% Convertible Senior Notes due 2015 (Old Notes), for a like principal amount of new 2.875% Series 2012 Convertible Senior Notes due 2015 (New Notes), and a cash payment.
Eli Lilly and Company and Boehringer Ingelheim today announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes.
BHR Pharma, LLC announced today the European Medicines Agency (EMA), responsible for evaluating medicines developed for use in the European Union, granted an orphan medicinal product designation for treating moderate and severe traumatic brain injury (TBI) to its proprietary intravenous progesterone infusion agent, BHR-100. The agent currently is being evaluated as a neuroprotective treatment for severe traumatic brain injury (TBI) in the global, Phase III SyNAPSe® clinical trial.
› Verified 4 days ago
Said M Issa, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2900 Golfside Dr, Suite 2, Ann Arbor, MI 48108 Phone: 313-724-2733 Fax: 313-724-2456 | |
Jill Elizabeth Bixler, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1000 Wall Street, Ann Arbor, MI 48105 Phone: 734-764-4190 | |
Paul P Lee, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1000 Wall Street, Ann Arbor, MI 48105 Phone: 734-764-4190 | |
Monte Anthony Delmonte, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1000 Wall St, Ann Arbor, MI 48105 Phone: 734-764-4190 | |
Denise Ann-marie John, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1000 Wall Street, Ann Arbor, MI 48105 Phone: 734-764-4190 | |
Brittany A Simmons, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1000 Wall St, Ann Arbor, MI 48105 Phone: 734-764-4190 | |
Alexander Valentine, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 1000 Wall St, Ann Arbor, MI 48105 Phone: 734-763-8122 |